Cell-mediated immunity in prostatic cancer

R. J. Ablin, R. A. Bhatti, S. Nagubadi, S. Zamora, P. D. Guinan

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Cell-mediated immunity to tumour in prostatic cancer patients was evaluated by slide and tube leukocyte adherence inhibition (LAI). Peripheral blood leukocytes from 56 of 73 (77%) patients with a confirmed histological diagnosis of adenocarcinoma of the prostate possessed significant reactivity to extracts of malignant prostate. Absence of significant reactivity with tissues other than malignant prostate and in 52 non-prostatic cancer patients, including 3 patients with prostatitis and 8 with prostatic hypertrophy, suggests immunity in prostatic cancer patients to what may presumptively be identified as prostatic tumour-associated antigens and tumour-associated immunity (TAI). Observation of the specific inhibition ('blocking') of TAI by a factor in autologous serum, i.e. the patient's serum, may be indicative of one means by which the potential effects of sensitized immunocompetent cells are inhibited in situ. Despite identification of TAI, a significant correlation between this immunity and the stage of disease, histological grade of tumour or therapy received was not demonstrable. Nonetheless, pending confirmation, the present results suggest implementation of a clinical trial of antigen-induced LAI as a potential routine diagnostic test for prostatic carcinoma.

Original languageEnglish (US)
Pages (from-to)253-264
Number of pages12
JournalClinical Oncology
Issue number3
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Cell-mediated immunity in prostatic cancer'. Together they form a unique fingerprint.

Cite this